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Nucleic acid sequence-based amplification assays for detection of human cytomegalovirus (HCMV) imme-
diate-early and pp67 mRNA in 65 amniotic fluid samples tested for prenatal diagnosis of congenital HCMV
infection showed sensitivity, specificity, and negative and positive predictive values >90%.
Prenatal diagnosis of congenital human cytomegalovirus
(HCMV) infection is mostly performed by rapid virus isolation
from, and/or PCR detection of viral DNA in, amniotic fluid
(AF) samples (1, 3, 11, 12, 14). In general, both techniques
have been shown to provide high specificity (96 to 100%) and
good sensitivity (70 to 90%) (4, 8, 10, 14, 15), with the excep-
tion of a few reports from a single group showing low speci-
ficity and positive predictive value for PCR on AF samples (5,
9). Since irrevocable decisions are often made on the basis of
prenatal diagnosis, the use of a confirmatory assay is highly
recommended. Thus, given the lack of cell culture facilities in
many laboratories, molecular assays which may confirm PCR
results for AF samples, thereby functioning as alternatives to
HCMV isolation, must be identified.
There are two commercially available assays for detection of
HCMV immediate-early (IE) and late pp67 mRNA using the
nucleic acid sequence-based amplification (NASBA) tech-
nique (BioMe´rieux, Boxtel, The Netherlands). The assay for
pp67 mRNA is available as a complete kit (NucliSens CMV
pp67), whereas a basic kit (NucliSens Basic Kit) is available for
IE mRNA detection; IE mRNA-specific primer sequences can
be obtained from BioMe´rieux. Currently, the NucliSens CMV
pp67 assay is approved by the Food and Drug Administration
for mRNA detection in blood, while the IE mRNA NASBA
basic kit is to be used for research purposes.
Overall, 65 AF samples from as many pregnant women with
primary HCMV infection during pregnancy were tested. Pri-
mary infection was diagnosed by either HCMV-specific immu-
noglobulin G (IgG) seroconversion or the presence of HCMV-
specific IgM associated with a low IgG avidity index (15). The
virologic outcome of pregnancy was ascertained in newborns
by HCMV isolation within the first 2 weeks of life and in
aborted fetuses by virus isolation from and histologic exami-
nation of fetal tissues. All AF samples had been previously
characterized for HCMV presence by both rapid virus isolation
on shell vial cultures and viral DNA amplification by PCR (16).
NASBA assays were performed retrospectively on AF sam-
ples according to the instructions given by the manufacturer
for pp67 mRNA detection in blood samples (NucliSens CMV
pp67). In particular, 49 AF samples collected from September
1991 through December 1999 and stored undiluted at 80°C
were diluted 1:10 in NucliSens lysis buffer (BioMe´rieux) upon
thawing. These samples were tested by NASBA for U1A
mRNA, the transcript of a cellular gene with a low rate of
transcriptional activity, to verify whether RNA was degraded
during storage (7). The remaining 16 samples, collected after
January 2000, were stored at 80°C as 1:10 dilutions in lysis
buffer. Nucleic acids were extracted from 100 l of AF by using
the NucliSens isolation kit (BioMe´rieux).
No RNA degradation was detected in the 49 samples stored
undiluted, as determined by U1A mRNA detection. Overall, of
the 65 samples tested, 29 were positive for HCMV by both
culture and DNA detection (reference assays), whereas 36
were HCMV negative by both techniques. As shown in Table
1, all 29 HCMV-positive samples were scored positive by both
IE and pp67 mRNA NASBA assays. On the other hand, of the
36 HCMV-negative samples, 36 were confirmed negative by
pp67 mRNA detection, whereas one sample tested positive for
IE mRNA. Thus, compared to virus isolation and DNA detec-
tion, IE and pp67 mRNA NASBA assays showed 98.5 (64 of
65) and 100% (65 of 65) concordance, respectively. However,
while all 29 congenital HCMV infections diagnosed antena-
tally were confirmed either at birth (17 newborns) or at au-
topsy following voluntary termination (12 fetuses), 2 out of 36
newborns with a prenatal diagnosis of no HCMV infection by
virus isolation and PCR were found HCMV infected at birth
(Table 1). In both cases congenital infection was asymptom-
atic. Neither of the two NASBA assays revealed the presence
of HCMV in AF samples from these two newborns (the only
IE mRNA-positive result obtained in this group did not con-
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TABLE 1. HCMV IE mRNA and pp67 mRNA NASBA results for
65 AF samples previously characterized by virus isolation and PCR
Virus isolation and
PCR result for
HCMV
No. of HCMV-positive AF
samples/no. examined
No. of newborns or
aborted fetuses with
congenital HCMV
infectionIE mRNA pp67 mRNA
Positive (n  29) 29/29 29/29 29
Negative (n  36) 1/36 0/36 2
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cern either one of these two congenitally infected newborns).
In addition, no U1A mRNA degradation was observed in these
two samples. Therefore, when referred to the virological out-
come, sensitivity, specificity, and negative and positive predic-
tive values for virus isolation, PCR, and pp67 NASBA were
found to be identical, i.e., 93.5, 100, 94.4, and 100%, respec-
tively (Table 2). As for IE mRNA, specificity and positive
predictive value were slightly lower (97.1 and 96.9%, respec-
tively), given the false-positive result for the group of unin-
fected fetuses.
The two false-negative results pertained to two fetuses
whose mothers suffered from primary HCMV infection at 11
and 16 weeks of gestation, respectively. In both cases, amnio-
centesis was performed at 23 weeks of gestation, and fetal
blood was negative for antigenemia, viremia, and DNAemia as
well virus-specific IgM.
This study shows that the presence of HCMV in AF samples
can be reliably detected by two commercial NASBA assays. In
fact, pp67 mRNA and IE mRNA NASBA assays showed 100
and 98.5% concordance, respectively, to DNA detection by
PCR and virus isolation by the shell vial assay. In particular, all
positive results obtained antenatally, with the exception of one
IE mRNA-positive result, were confirmed at birth, thus sup-
porting the high specificity of PCR results as previously re-
ported by us and other groups (3, 4, 6, 10, 11, 14–17). The
discordant result obtained by the IE mRNA NASBA assay in
the group of negative AF samples is difficult to explain. The
sample, stored at 80°C since 1998, was tested two additional
times with discordant results, thus indicating a low-level posi-
tivity.
On the other hand, none of the assays included in the
present study provided 100% sensitivity. False-negative results
represent a well-known problem of prenatal diagnosis of con-
genital HCMV infection. This problem has been shown to be
only partially overcome by (i) increasing the sensitivity of the
PCR techniques employed for HCMV detection in AF sam-
ples (16), (ii) waiting at least 6 to 8 weeks after the onset of
maternal infection before fetal sampling (1, 10, 11, 13), and
(iii) performing the procedure after 21 weeks of gestation (2,
10, 11). Indeed, notwithstanding the adoption of these precau-
tions, false-negative results due to the delayed transmission of
the infection may still be encountered, although infrequently.
However, since false-negative results were associated with lack
of symptoms at birth, a sensitivity of greater than 90% (the top
now achievable) may be considered satisfactory.
In conclusion, this study shows that both IE and pp67
mRNA NASBA assays can be reliably performed to detect
HCMV in AF samples. Therefore, they can be used as first-
choice assays or assays to confirm results obtained by PCR in
those laboratories where virus isolation is not performed. In
fact, all but one of the positive mRNA results obtained ante-
natally in this study were confirmed at birth. In addition, it has
been shown that HCMV mRNA can be successfully detected
in AF samples stored at 80°C for more than 10 years.
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